Venture Partner at Lightspeed Venture Partners
Jonathan MacQuitty focuses on life science and healthcare investments. He was formerly a partner at Abingworth, a trans-Atlantic life science venture capital firm, heading up the firm’s West Coast office. Since May 2015, he has been the initial CEO of Forty Seven Inc. Forty Seven is a Lightspeed portfolio company developing immuno-oncology therapeutics to treat various cancers. The technology was licensed out of Stanford University in 2015. The company’s lead product is currently in two different clinical studies. Jonathan is also Chairman of Personalis, another Lightspeed portfolio company which is commercializing human genomic analysis for cancer research and diagnosis.